Abstract: G protein-coupled receptors (GPCRs) remain primary therapeutic targets for numerous cardiovascular disorders, including heart failure (HF), because of their influence on cardiac remodeling in response to elevated neurohormone signaling. GPCR blockers have proven to be beneficial in the treatment of HF by reducing chronic G protein activation and cardiac remodeling, thereby extending the lifespan of patients with HF. Unfortunately, this effect does not persist indefinitely, thus next-generation therapeutics aim to selectively block harmful GPCR-mediated pathways while simultaneously promoting beneficial signaling. Transactivation of epidermal growth factor receptor (EGFR) has been shown to be mediated by an expanding repertoire of GPCRs in the heart, and promotes cardiomyocyte survival, thus may offer a new avenue of HF therapeutics. However, GPCR-dependent EGFR transactivation has also been shown to regulate cardiac hypertrophy and fibrosis by different GPCRs and through distinct molecular mechanisms. Here, we discuss the mechanisms and impact of GPCRmediated EGFR transactivation in the heart, focusing on angiotensin II, urotensin II, and b-adrenergic receptor systems, and highlight areas of research that will help us to determine whether this pathway can be engaged as future therapeutic strategy.
INTRODUCTION
G protein-coupled receptors (GPCRs) are a large family of 7 transmembrane-spanning proteins that mediate responses to a diverse array of external stimuli including hormones, neurotransmitters, odorants, and photons. GPCRs are known to play a role in the development of cardiovascular disorders, such as hypertension and heart failure (HF), and therapeutics that target GPCRs constitute ;40% of currently used drugs, demonstrating their continued importance as pharmacological targets. Stimulation of GPCRs initiates a number of signaling pathways to regulate extensive cellular responses, which in the heart includes contractility, hypertrophy, proliferation, survival, and fibrosis (Fig. 1A) . [1] [2] [3] [4] While the proximal mechanisms relaying GPCR signals are now commonly recognized to include engagement of G protein-and/or GPCR kinase (GRK)/b-arrestin (barr)-dependent pathways, 4 the distal mechanisms that regulate cardiac cell behavior are divergent and vary by cell type and pathophysiologic status. Understanding how these mechanisms regulate cardiac remodeling during disease progression remains a fundamental goal of cardiac GPCR research and development of therapeutics. One such mechanism that has been shown to modulate various aspects of cardiac remodeling downstream of GPCRs is through transactivation of epidermal growth factor receptor (EGFR).
EGFR is a receptor tyrosine kinase, of which there are 4 closely related members: EGFR (ErbB-1, HER1), HER2 (ErbB2/neu), HER3 (ErbB3), and HER4 (ErbB4). While ErbB2-4 is beginning to be studied more frequently for its potential roles in the regulation of cardiomyocyte proliferation and cardiotoxicities related to cancer therapeutics, [5] [6] [7] [8] EGFR is the most well-characterized family member in the heart. Several endogenous ligands, including epidermal growth factor (EGF), heparin-binding EGF (HB-EGF), and transforming growth factor a, 9,10 bind EGFR to induce dimerization or stabilization of an existing dimer and allow transphosphorylation of C-terminal tyrosine residues by the kinase domain, thereby engaging various signal transduction pathways. 11 EGFR was first shown to be activated by GPCRs 20 years ago when Ullrich's group reported that EGFR phosphorylation increased after treatment with several GPCR agonists including endothelin and thrombin, which could be blocked using an EGFR inhibitor or a dominant-negative mutant EGFR. 12 Since the initial discovery of GPCR-dependent EGFR transactivation, an increasing number of GPCRs have been identified as being capable of transactivating EGFR, including adenosine, 13, 14 adrenergic, [15] [16] [17] [18] [19] [20] aldosterone, 21 angiotensin II, [22] [23] [24] [25] bradykinin, 26 d-opioid, 27 endothelin-1, 28,29 muscarinic, 30 prostaglandin E2, 31 protease-activated, 32, 33 sphingosine-1-phosphate 34 , and urotensin II [35] [36] [37] receptors. A growing body of evidence demonstrates that GPCR-mediated EGFR transactivation occurs in the heart, playing potentially important roles in both normal physiology and pathophysiology (Table 1) .
which GPCR stimulation may lead to EGFR-dependent signaling, often occurring in both GPCR-and cell-specific manners, through either intracellular or extracellular pathways, as previously reviewed. 39 Briefly, GPCR stimulation rapidly leads to both G protein-dependent and GRK/barrdependent signaling responses, either of which may lead to EGFR transactivation. Several GPCRs induce EGFR activation through matrix metalloprotease (MMP)-mediated or a disintegrin and metalloprotease (ADAM)-mediated cleavage of extracellular EGFR ligand, often HB-EGF, which can be induced in either a G protein-or GRK/barr-dependent manner. While this process typically involves intermediate signaling adapters or kinases such as Src, it was recently shown that Gbg subunits can directly activate MMP14 via to induce HB-EGF cleavage and EGFR transactivation in cardiac myocytes and fibroblasts. 25 Thus, in a GPCR-and cell type-specific manner, EGFR transactivation may be engaged through multiple mechanisms (Fig. 1B) .
In addition to intermediate signaling components, some GPCRs structurally interact with EGFR in absence of receptor ligands which may enhance the efficiency of EGFR transactivation or focus the downstream signaling response to particular subcellular locales. [40] [41] [42] Such multireceptor complexes may form on membrane microdomains, because blockage of lipid rafts has been demonstrated to disrupt a specific interaction between EGFR and the bile acid receptor TGR5. 43 This may be an especially important concept with respect to fully differentiated adult cardiomyocytes that are known to have sarcolemmal microdomains containing various GPCRs, 44 some of which, such as b2AR, have been well FIGURE 1. The influence of GPCR-mediated EGFR transactivation on cardiac remodeling processes. A, Prolonged neurohormone stimulation of cardiac-expressed GPCRs leads to changes in cardiac remodeling, including myocyte survival and hypertrophy, fibroblast proliferation, fibrosis, and inflammation. Blockers of these GPCR systems are commonly used to decrease cardiac remodeling during conditions such as HF. B, GPCR-mediated EGFR transactivation influences numerous cardiac remodeling processes and may occur through mechanisms including either G protein-or GRK/ barr-dependent signaling in a GPCR-and cell type-specific manner. Research areas requiring further development include (1) the proximal mechanism of EGFR transactivation by specific GPCRs, (2) the mechanism and contribution of GPCR-EGFR association in mediating transactivation-dependent outcomes, and (3) the distal signaling pathways unique to specific GPCR-EGFR complexes that may influence cardiac remodeling. after stimulation with ISO, but dissociated in response to EGF, 41 while stimulation of an angiotensin type 1A receptor (AT1R)-EGFR complex with either AngII or EGF increased its association in a temporal manner. 42 The impact of receptor ligands on modulation of GPCR-EGFR interaction seems to be dependent on the GPCR-EGFR complex in particular and may suggest different mechanisms of both basal and poststimulation association with EGFR. Although barr-dependent signaling has been implicated in maintaining or increasing b-adrenergic receptor (bAR) association with EGFR after catecholamine stimulation, 40, 41 less is known about the actual structural requirements at the receptor level that allow for EGFR association.
Regarding b1AR, it was shown that mutation of all the putative C-terminal GRK phosphorylation sites almost completely abolished its ability to interact with EGFR, even under nonstimulated conditions. 41 Whether this was due to a GRKspecific effect or occurred as a by-product of a structural change in the C-terminus of b1AR is not known, although another study showed that the third intracellular loop and a portion of the C-terminus of AT2R was required for interaction with ErbB3. 46 Similarly, current knowledge regarding the specific region of EGFR that is responsible for GPCR interaction is lacking. However, it has been reported that the juxtamembrane domain of EGFR binds Gs protein and that an increase in Gs activity disrupts this interaction; 47 thus, the juxtamembrane domain of EGFR could serves as a point of association with Gs protein-coupled receptors.
After ligand binding and EGFR dimerization, C-terminal transphosphorylation leads to adapter protein recruitment and formation of signaling networks. 48 EGFR has numerous tyrosine phosphorylation sites in its C-terminus, and distinct phosphorylation patterns may occur in response to differential activation by various GPCRs, which could result in the recruitment of unique sets of adaptor proteins. 49 This concept is similar to the "Barcode Hypothesis" for GPCRs where distinct phosphorylation patterns, or barcodes, on the C-terminal tail of GPCRs have been shown to produce differences in adapter protein recruitment. [50] [51] [52] [53] Although differential EGFR phosphorylation patterns have been observed in response to EGF stimulation in distinct cell lines, 48 the impact of transactivation by various GPCRs on EGFR phosphorylation patterns has not been extensively investigated. Indeed, a majority of studies have reported the impact of GPCR-mediated transactivation on phosphorylation of a limited number of tyrosine residues in the C-terminus of EGFR. However, unique GPCR-mediated EGFR phosphorylation patterns could contribute to divergent adapter protein recruitment, network formation, and downstream signaling responses produced in different cardiac cell types in response to different ligands, processes that await discovery.
IMPACT AND IMPLICATIONS OF GPCR-DEPENDENT EGFR TRANSACTIVATION
An expanding cohort of GPCRs (as listed above) has been shown to influence cardiac remodeling, including hypertrophy, fibrosis, and survival, through the transactivation of EGFR. Here, we focus our discussion on 3 GPCR systems [AT1R, urotensin II receptor (UTIIR), and bAR] with distinct G protein-coupling characteristics and how they may engage EGFR to elicit changes in cardiac remodeling processes.
AT1R
Angiotensin II (AngII), acting through AT1R, has been demonstrated to relay both prohypertrophic and profibrotic effects through EGFR transactivation in the heart. For instance, AngII infusion-induced pathological cardiac remodeling in vivo was shown by several groups to be largely abrogated by EGFR inhibition, by siRNA targeting EGFR, 54 coinfusion with the EGFR inhibitor erlotinib 55 , or overexpression of inhibitors of EGFR signaling, including receptor-associated late transducer (RALT) 56 and a dominantnegative EGFR mutation. 57 At a cellular level, AT1R enhances both cardiomyocyte hypertrophy and cardiac fibroblast proliferation. AT1R-mediated EGFR transactivationsensitive neonatal cardiomyocyte hypertrophy was initially demonstrated to require Gaq protein activation, MMP activation, and downstream ERK signaling 24 but was insensitive to protein kinase C (PKC) inhibition. Similarly, AngII treatment of cardiac fibroblasts was demonstrated to enhance EGFR phosphorylation and downstream ERK activation, leading to increased c-Fos expression and DNA synthesis in a PKCindependent manner. 22 Instead, these responses were sensitive to treatment with the EGFR inhibitor AG 1478, a dominantnegative EGFR mutant, a Ca 2+ chelator, or Ca 2+ /calmodulin kinase inhibitors. Furthermore, DNA synthesis was unaffected by the addition of an anti-EGF antibody to the culture media and conditioned media taken from AngII-treated cells, suggesting an intracellular activation mechanism.
While the distal responses to AT1R-mediated EGFR transactivation appear to commonly involve ERK activation, the proximal mechanism(s) linking AT1R stimulation to EGFR transactivation-mediated effects on these processes are varied and somewhat controversial. While AT1R couples to both Gq/11 and G12/13 protein families, 4 Gq proteinmediated AT1R signaling was initially associated with EGFR transactivation-dependent effects on cardiac remodeling, although Gq protein-independent signaling through phosphorylation of AT1R at Tyr319 was later shown to contribute to remodeling processes. It was postulated that Tyr319 allowed binding with SHP2 to mediate interaction with and transactivation of EGFR and an AT1R-Y319F mutant no longer induced cardiac fibroblast proliferation. 58 In fact, transgenic mice overexpressing AT1R-Y319F did not develop cardiac hypertrophy, in contrast to mice overexpressing WT-AT1R, and were resistant to AngII infusioninduced hypertrophy, cardiomyocyte apoptosis, and fibrosis, similar to mice overexpressing a dominant-negative EGFR. 23 In addition, PKC, STAT3, ERK, Akt, and Gaq activation were unaltered in Tg-Y319F mice compared with Tg-WT, suggesting that these pathways are not involved in the adverse effects of AngII treatment. However, more recent work has again highlighted the importance of AT1R-Gq protein-dependent EGFR transactivation in mediating cardiomyocyte hypertrophy, 59 independent of Tyr319, and an elegant screening study identified numerous kinases that are likely to be involved in transmitting AT1R stimulation to EGFR transactivation, confirming roles for triple functional domain/PTPRF interacting (TRIO), bone marrow kinase in chromosome X (BMX), and choline kinase a in the process. 60 BMX, a nonreceptor tyrosine kinase, was subsequently shown to be involved in AngII-mediated cardiac hypertrophy, although the impact of BMX on EGFR transactivation was not specifically investigated in this study. 61 Thus, the role these newer targets play in AT1R-dependent EGFR transactivation-induced cardiac hypertrophy or fibrosis remains to be directly tested.
UTIIR
Stimulation of UTIIR, upregulated during congestive HF in human hearts, 62 also leads to EGFR transactivation in both in vitro and in vivo models. Urotensin II (UII) treatment has also been shown to engage EGFR transactivation in neonatal cardiomyocytes, independent of PKC, PI3K, or Ca 2+ mobilization, leading to increased ERK and p38 activity and resulting in hypertrophy. 36 This effect on cardiomyocyte hypertrophy has also been shown to involve the generation of reactive oxygen species, which oxidize and inhibit the activity of the phosphotyrosine phosphatase SHP2, thus increasing EGFR activation. 37 UII-induced reactive oxygen species generation was also shown to relay EGFR transactivation in cardiac fibroblasts, leading to enhanced ERK activation and proliferation. 63 Like AT1R, UTIIR also couples to Gq protein to exert many of its effects; 64 however, it has also been demonstrated to signal through Gi protein, although an essential role for either G protein in relaying EGFR transactivation has not been defined. Indeed, G protein-independent signaling may be more crucial for UII-induced EGFR transactivation because UII treatment of HEK 293 cells initiated barr-dependent EGFR transactivation and internalization, which was essential for relaying a decrease in cell death. 35 Regardless of the proximal mechanisms involved, blocking UTIIR using the UTII antagonist urantide in a mouse model of pressure overload (transaortic constriction) was shown to worsen cardiac function, fibrosis and cell death outcomes, and changes associated with decreased EGFR and ERK phosphorylation. 35 Thus, the cardiac urotensin II-EGFR signaling system may represent an as-yet untapped therapeutic target for HF drug development.
bARs Both b1AR and b2AR have been shown to interact with EGFR and mediate its transactivation using a similar molecular mechanism. Both bAR isoforms rely on G proteinindependent, GRK/barr-dependent signaling to promote Src-and MMP-mediated HB-EGF shedding and subsequent EGFR activation. 15, 16, 40, 65 In addition, PI3K-dependent Src activation is required for b2AR-mediated EGFR transactivation and significantly increases their association in a multireceptor complex. 45 While the b1AR-EGFR complex does not appear to be enhanced on b1AR stimulation, GRK/barr-dependent signaling is required to maintain their association in HEK 293 cells. 41 b1AR-EGFR association also occurs in the human heart 41 and adult feline ventricular cardiomyocytes (AFVM , Fig. 2) ; however, the kinetics of complex association after b1AR stimulation appears to differ among different model systems. While b1AR-EGFR association can be observed for prolonged time points after treatment with ISO in HEK 293 cells, 41 activation of b1AR in AFVM results in rapid colocalization with internalized EGFR and barr2, but at longer time points is largely recycled back to the sarcolemmal membrane while EGFR undergoes prolonged internalization, including perinuclear localization (Fig. 2) .
As with other GPCRs, ERK activity is increased distal to b1AR-dependent EGFR transactivation and, along with enhanced Akt activation, this mechanism promotes cardiomyocyte survival, 16, 18, 66 whereas in cardiac fibroblasts, b2AR-mediated transactivation leads to increased DNA synthesis and mitogenesis. 15 An initial investigation of the subcellular localization of signaling in response to b1AR-mediated EGFR transactivation were performed in HEK293 cells and showed that activated ERK was restricted to the cytosolic compartment, with no nuclear accumulation observed even after 60 minutes of stimulation. 41 In contrast, direct EGFR stimulation with either EGF or HB-EGFinduced rapid nuclear accumulation of ERK, within 5 minutes, that persisted for 60 minutes and resulted in the activation of the transcription factor Elk-1, suggesting that b1AR-mediated EGFR transactivation provides a mechanism to restrict EGFR signaling to cytosolic processes. However, subsequent studies in primary neonatal rat cardiomyocytes and in whole mouse hearts demonstrated that bAR-mediated EGFR transactivation actually resulted in nuclear accumulation of activated ERK and Akt. 18 Furthermore, our group discovered a role for EGFR transactivation-dependent repression of TRAIL, a proapoptotic factor whose decreased expression promoted cardiomyocyte survival. 18 Subsequently, we detailed both the acute and chronic transcriptome responses to bAR-mediated EGFR transactivation in the mouse heart, with foci on apoptotic genes and cytokines, including thrombospondin 1, Ccl2, and TNFa. 38, 67 Coupled with perinuclear localization of EGFR after b1AR stimulation observed in AFVM (Fig. 2) , our cumulative studies suggest that in relevant primary cardiomyocyte and whole heart systems, bAR-mediated EGFR transactivation influences survival, hypertrophy, and fibrosis through dynamic regulation of the transcriptome. 18, 38, 67 In vivo studies to date do indeed demonstrate that chronic catecholamine stimulation leads to increased cardiac cell death, fibrosis, and hypertrophy with decreased function, all of which are sensitive to EGFR inhibition. However, use of different EGFR inhibitors in vivo resulted in different outcomes, wherein erlotinib worsened cardiac dilation, decreased cardiac function, and increased cell death in response to chronic ISO infusion, 16 whereas gefitinib reduced ISO-induced cardiac dysfunction, hypertrophy, and cell death, but increased fibrosis on its own. 38 These disparate results could arise from EGFR-independent, off-target effects because gefitinib and erlotinib each interact with a wide array of kinases. 68 For instance, Fabian et al demonstrated that gefitinib binds to at least 18 kinases and erlotinib to 23, with only 12 of these kinases shown to commonly bind to both. 68 Such off-target effects could explain differences in bARmediated cardiac remodeling responses in the presence of an EGFR inhibitor and provide caution for in vivo pharmacologic studies. Thus, more refined in vivo models, preferably genetic and cell type-specific, are essential to better understand the impact of bAR-mediated EGFR transactivation in the heart. Although bAR-mediated EGFR transactivation shows promise as a cardioprotective pathway, it has been difficult to characterize. A major hurdle to defining its impact in cardiomyocytes has been the reliance on loss-of-function analyses using EGFR inhibitors in the presence of an unbiased bAR agonist. While suggestive of the impact of this pathway on processes such as survival, EGFR inhibitors do not directly measure the contribution of EGFR transactivation in the absence of G protein-dependent bAR signaling. The orthosteric nonselective b-blocker carvedilol has been shown to induce barr-biased bAR-mediated signaling, including EGFR transactivation [69] [70] [71] ; however, these studies were performed either in HEK 293 cell systems with exogenous receptor expression or in whole hearts using a very high dose of carvedilol with no functional insight at a contractile level. Indeed, it has recently been demonstrated that carvedilol does not enhance cardiomyocyte contractility, 65 likely because of its inverse agonist properties. 72 Furthermore, a recent metaanalysis revealed a lack of clinical difference between carvedilol versus the unbiased b-blocker metoprolol succinate in patients with HF. 73 Taken together, these data indicate that although carvedilol may have the capacity to induce barrbiased bAR signaling and EGFR transactivation, it likely does not occur at therapeutically relevant doses, and if doses were increased to achieve such biased signaling, it may be at the expense of cardiac contractility. Future advancements in understanding both the molecular mechanisms and functional outcomes of bAR-mediated EGFR transactivation in cardiac cells and the whole heart are therefore likely to stem from next-generation biased bAR ligands that can selectively activate the EGFR pathway.
CONCLUSION
An ongoing question in the field is how a single receptor, EGFR, can produce distinct effects and physiological outcomes depending on its mode of activation. Acting as a nodal input for numerous GPCRs, EGFR has the potential to fine-tune neurohormone signals both physiologically and pathologically. From in vitro cell model studies, various mechanisms of transactivation have been identified that can be engaged by distinct receptor systems; however, how it is all put together in a meaningful way in fully differentiated cardiomyocytes or more generally in the whole heart in vivo is not well understood. Dynamic subcellular distribution of EGFR with various GPCRs and proximal regulators likely plays a role in the integration of such signals, but there have been major barriers to studying EGFR-sensitive cardiac GPCR signaling effects in vivo. EGFR KO mice are embryonic lethal, and another genetic model that used constitutive vascular smooth muscle cell/cardiomyocyte EGFR loss was unable to dissociate the impact of EGFR deletion in vascular smooth muscle cell from cardiomyocytes on remodeling in an adult HF model. 74, 75 Furthermore, pharmacologic studies using EGFR inhibitors are fraught with interpretability issues, especially regarding agent selectivity profiles, 68 and have produced variable and conflicting reports regarding the impact of EGFR inhibition on cardiac function and survival. 13, 16, 38, 76, 77 These issues have prevented succinct in vivo analysis of the impact of GPCR-mediated EGFR transactivation on cardiac function and survival during HF or even EGFR signaling in more generalized contexts of HF. Future work on the impact of GPCR-mediated EGFR transactivation on cardiac function and remodeling in relevant in vivo systems will thus benefit from the development of refined genetic models.
